DIRS.INFO The most relevant business & tech news

☆ Goldman Sachs upgrades BioNTech to buy, sees stock surging more than 25%
▼ + stars: | 2024-11-08 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +1 min

Goldman Sachs is optimistic on BioNTech as a result of a new oncology asset. The bank upgraded shares of the German biotechnology firm to a buy rating from neutral. Analyst Chris Shibutani accompanied the move by hiking his price target to $137 from $90, which implies upside of $27%. BNTX YTD mountain BNTX YTD chart BioNTech can also support an innovative and expansive clinical development program for BNT327 that could challenge the status quo of immune-oncology regimens, Shibutani added. Of the 19 who cover it, 12 have buy or strong buy ratings on BioNTech, LSEG data shows.

Persons: Goldman Sachs, Chris Shibutani, BNTX

☆ Here are Tuesday's biggest analyst calls: Nvidia, Apple, Walmart, Salesforce, Starbucks, Amazon & more
▼ + stars: | 2024-09-24 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Here are Tuesday's biggest calls on Wall Street: Piper Sandler initiates Colgate-Palmolive and Church & Dwight as overweight Piper said both consumer products company offer an attractive risk/reward. Piper Sandler upgrades Salesforce to overweight from neutral Piper said it sees an attractive risk/reward for the stock. Bernstein reiterates Amazon as outperform Bernstein said advertising is "key to the bull case once again" for Amazon. Wedbush upgrades Comerica to outperform from neutral The firm added the regional bank to its best ideas list. " CFRA reiterates Nvidia as buy The firm says it sees Nvidia with "sustained compute demand" over the coming years.

Persons: Piper Sandler, Dwight, Piper, Baird, Jefferies, it's bullish, Raymond James reinstates Uber, Raymond James, Goldman Sachs, Goldman, KeyBanc, Morgan Stanley, immuno, Oppenheimer, Lowe's, Redburn, it's, Truist, Baird downgrades McKesson, Needham, Apple, Pinterest, Leerink, Guggenheim, Tesla, TSLA, Bernstein, CFRA Organizations: Colgate, Palmolive, Church, Jefferies, Starbucks, Avidity Biosciences, BP, Exxon, Costco, Walmart, Apple, GE Vernova, UBS, Citi, Mastercard, Visa, U.S, DOJ, Comerica, CMA, Nvidia

☆ Multivitamins aren't a 'cheat pill' and not everyone needs to take them, doctor says—focus on this instead
▼ + stars: | 2023-11-30 | by ( Renée Onque | ) www.cnbc.com time to read: +1 min

You probably know at least one person who swears by taking a daily multivitamin — or you take one yourself. Nearly a quarter of U.S. teens and children, ages 19 and under, took a multivitamin within that same time period. Multivitamins can be taken in several different forms including gummies, capsules and even liquids, which are growing in popularity. The search term "liquid multivitamins reviews" has 6 million views on TikTok. But here's what Ko suggests doing instead of buying multivitamins, if you're generally in good health.

Persons: Elizabeth Ko, Ko Organizations: Centers for Disease Control, UCLA, Integrative Medicine, CNBC

☆ 2 essentials this doctor stocks up on every cold and flu season: 'I try to avoid taking OTC medications if I can'
▼ + stars: | 2023-11-28 | by ( Renée Onque | ) www.cnbc.com time to read: +4 min

Honey For years, people have claimed that eating honey, especially locally-collected honey, is a great way to lessen seasonal allergies. I use honey for the common cold, and it's perfectly safe. "I use honey for the common cold, and it's perfectly safe." Around cold and flu season, Mafi stocks up on garlic for symptom relief for colds. "There is a small amount of evidence that garlic can help reduce the severity and duration of the common cold," Mafi says.

Persons: John Mafi, Mafi, Honey, Timothy Wong, I've, didn't Organizations: Food and Drug Administration, General Internal Medicine, Health Services Research, David Geffen School of Medicine, UCLA, CNBC, British Medical, American Academy of Pediatrics, Cochrane

☆ Vitamin C and D supplements aren't a magical remedy, doctor says: Use these 5 tried-and-true immuno-boosters
▼ + stars: | 2023-11-07 | by ( Renée Onque | ) www.cnbc.com time to read: +1 min

But does that mean stocking up on vitamin C and vitamin D? and that's where the role of vitamin supplementation comes into play," Ben-Aderet says. "Truth is, there's never been any proven clinical benefit for vitamin supplementation in individuals that are able to get a normal, healthy diet and don't have a clinical vitamin deficiency. DON'T MISS: Do Americans have a vitamin D problem? Here’s what health experts say: ‘You have to be really careful’Though he notes that some people have severe, medical vitamin C and vitamin D deficiencies — which can lead to swollen, bleeding gums or bone fractures — and for those individuals, vitamin supplementation is a very effective and necessary measure.

Persons: Michael Ben, Ben, Aderet, there's Organizations: Sinai Medical Locations: America

Hong Kong CNN —US drugmaker Moderna has signed a deal to make mRNA medicines in China as part of its first major investment in the country, despite escalating trade and political tension between Washington and Beijing. The company currently only markets its mRNA vaccines for Covid-19, but has a number of vaccines and therapeutics in its pipeline. Those focus on addressing infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases, according to the company. Moderna’s Covid-19 vaccine, which received emergency authorization from US regulators in 2020 and full approval in 2022, has not been approved in China. For most of the pandemic, China relied on more traditional platforms for its homegrown Covid-19 vaccines.

Persons: Yicai, Janet Yellen, Biden, Moderna’s, Johnson Organizations: Hong Kong CNN, CNN, Xinhua, CSPC Pharmaceutical Group, Pfizer Locations: Hong Kong, China, Washington, Beijing, The Cambridge , Massachusetts, Shanghai’s Minhang, Shijiazhuang

☆ Australia to expand rollout of fifth COVID vaccine shot
▼ + stars: | 2023-02-08 | by ( ) www.reuters.com time to read: +1 min

The decision expands eligibility for the booster shot to include about 14 million people, more than half the country's population, who will be offered Omicron variant-specific vaccines from Feb. 20, Butler said. Only severely immuno-compromised people had been recommended to take a fifth dose until now, the advice being to receive the booster three months after their fourth shot. The rollout of the fifth shot will help "deal with what inevitably will be the next phase of the next wave of COVID sometime over the course of 2023," Butler said. The government also has made the fourth dose eligible for all aged 18-29 after Australia's immunisation advisory group updated its recommendations. Only people above 30 or the immuno-compromised group were recommended for a fourth dose previously.

☆ JPMorgan says this biotech stock could rally 60%
▼ + stars: | 2023-01-24 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

JPMorgan has moved off the sidelines on Allogene Therapeutics , a clinical-stage immuno-oncology company the bank believes could see positive catalysts. Analyst Brian Cheng upgraded the stock to overweight from neutral. Cheng also cut his price target nearly in half to $11 from $20, but the new forecast implies the stock will gain 60.3% over the next year. The CD19 franchise is centered around studies for relapsed or refractory non-Hodgkin lymphoma. The analyst noted that one concern about the company is the state of its BCMA franchise, which is focused on treatments for relapsed and refractory multiple myeloma.

☆ Biotech investor Brad Loncar shares 10 predictions for 2023, including a hot new cancer target, Nobel Prize winners, and a biotech founder running for president
▼ + stars: | 2023-01-04 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +14 min

Loncar shared his 2023 forecast, including new drugs, Nobel Prize winners, and more globalization. Brad Loncar isn't expecting a miraculous rebound for the biotech industry in 2023. In an interview with Insider, Loncar shared 10 predictions for biotech in 2023, ranging from Nobel Prize winners and presidential runs to hot cancer targets and bankruptcy worries. 2022 was a rough year for the biotech industry, which once again underperformed the stock market. The industry runs to the next super-hot cancer target: Claudin 18.2In cancer research, drug companies are always on the hunt for the next promising target.

☆ Moderna just used a personalized vaccine to treat cancer, and it could signal a major breakthrough in how we treat the disease
▼ + stars: | 2022-12-13 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +4 min

Moderna's cancer vaccine lowered the risk of death or skin-cancer recurrence in a midstage study. Moderna's CEO Stéphane Bancel compared the cancer study results to the initial outbreak of COVID-19, when Moderna scrambled to respond and develop a vaccine. Bancel said Moderna and its partner, Merck, would launch multiple late-stage studies in 2023 to test the cancer vaccine in not just melanoma patients but other types of cancer. Merck paid $250 million earlier this year to jointly develop Moderna's vaccine, extending a partnership between the two drugmakers that began in 2016. Study results have yet to be presented at a conference or published in a journal.

☆ Sanofi says any offer for Horizon Therapeutics, if made, will be in cash
▼ + stars: | 2022-12-02 | by ( Dominique Vidalon | ) www.reuters.com time to read: +1 min

PARIS, Dec 2 (Reuters) - French drugmaker Sanofi (SASY.PA) said on Friday that if it decides to bid for biotech company Horizon Therapeutics Plc (HZNP.O), it would do so in cash. Horizon Therapeutics Plc, which has a market capitalization of about $18 billion, is in talks with Amgen Inc (AMGN.O), Sanofi (SASY.PA) and Johnson & Johnson (JNJ.N) unit Janssen Global Services over potential takeover offers. "Any offer for Horizon Therapeutics Plc (HZNP.O), if made, would be in cash, as required by Rule 2.12 of the Takeover Rules," Sanofi said in a statement. "There is no certainty that any offer will be made, nor as to terms on which any such offer may be made, if forthcoming," it added. Horizon, which makes drugs for rare, autoimmune and severe inflammatory diseases, has said there is no certainty that it will receive a takeover offer.

☆ This under-the-radar stock can surge more than 60% on a possible treatment for immuno-inflammatory diseases, Goldman Sachs says
▼ + stars: | 2022-12-01 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Shares of Aclaris Therapeutics can surge more than 60% on the back of a possible new treatment for immuno-inflammatory diseases, including rheumatoid arthritis, according to Goldman Sachs. Analyst Corinne Jenkins initiated coverage of Aclaris Therapeutics with a buy rating, saying she expects promising results out of clinical trials for the company's drug called zunsemetinib . The biopharma stock has already outperformed this year, up nearly 5% in 2022, while the S & P 500 declined roughly 14%. The analyst expects that there will be further catalysts for positive upside as the Aclaris unveils further data for zunsemetinib in 2023. "We see this profile as sufficient to garner modest share in these large indications, fostering a sizable peak sales opportunity which we estimate at > $5B across indications," Jenkins wrote.

☆ Stocks making the biggest moves midday: Salesforce, Five Below, Okta, Costco and more
▼ + stars: | 2022-12-01 | by ( Samantha Subin | ) www.cnbc.com time to read: +4 min

Salesforce did report earnings and revenue that beat analyst expectations for the most recent quarter, however. Costco – Shares of retailer Costco shed nearly 6% after the company reported softer-than-expected sales figures for November that could signal a weak consumer heading into the holiday shopping season. The cloud data platform provider reported earnings that beat expectations but provided light revenue guidance, which sent the stock lower after-hours Wednesday. The company reported 29 cents of earnings per share on $645 million of revenue. The lingerie company reported earnings of 29 cents per share on revenue of $1.32 billion.

☆ Horizon Therapeutics fields buyout interest from Amgen, J&J and Sanofi
▼ + stars: | 2022-11-29 | by ( ) www.reuters.com time to read: +1 min

The biotech company, with a market capitalization of about $18 billion, is in talks with Amgen Inc (AMGN.O), Sanofi (SASY.PA) and Johnson & Johnson (JNJ.N) unit Janssen Global Services. Amgen acquired ChemoCentryx in a $4 billion deal in October, while J&J earlier this month announced a $16.6 billion bid for Abiomed (ABMD.O). Sanofi earlier this year completed the buyout of immuno-oncology company Amunix Pharmaceuticals for around $1 billion. Amgen declined to comment on the talks, while Sanofi and Janssen Global were not immediately available. Horizon expects over $4 billion in global annual peak sales for its biggest drug Tepezza, which is used to treat thyroid eye disease.

Organizations: & $

☆ A series of mega-blockbuster drugs are on the horizon. How to invest in the trend
▼ + stars: | 2022-10-08 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +4 min

"That said, the biggest drugs usually feature one, or best case two, of these attributes." Seven drugs on Meacham's list are already in the market, and have already hit the $10 billion or more benchmark. That means some of these drugs may be already hitting the end of their peak sales period. Meacham has previously said that one of the drugs in this bucket, Eli Lilly's tirzepatide, could be the first $100 billion drug . But many investors are hopeful about its potential as an obesity treatment .

☆ Licitație cu iz de dedicație pentru livrarea vaccinului anti-Covid
▼ + stars: | 2021-03-25 | by ( Daniela Calmis | ) www.zdg.md time to read: +13 min

Cu alte cuvinte, orice vaccin de pe piață este eligibil pentru a fi cumpărat de către Guvernul R. Moldova. În total, 10 vaccinuri anti-COVID-19 sunt aprobate pe teritoriul R. Moldova de către Comitetul Național Consultativ de Experți în domeniul imunizărilor. „Tetis International Co” deține în R. Moldova Centrul de imunizare „Immuno+”. Vaccinul rusesc Sputnik V a fost lobat insistent în ultimele luni de către Igor Dodon, fostul președinte al R. Moldova, partidul căruia încă gestionează Guvernul R. Moldova. Totodată, experta afirmă că unele condiții de desfășurare a licitației și a negocierilor cu producătorii de vaccin tind să favorizeze anumiți producători de vaccin.

Persons: CAPCS, Maia Sandu, Johnson, Janssen, Johnson & Johnson ., Constantin Nedelea, Nedelea . Oficialul, Nedelea, ZdG, Serghei Prepeliță, Igor Prepeliță, Prepeliță, Igor Dodon, ., Moldova . Dodon, Ala Organizations: Agenția Europeană, Organizației Mondiale a Sănătății ( OMS, OMS, Agenția Medicamentului, Sputnik, Johnson &, Președinția, Ministerul Sănătății, Federația Rusă ., FDA, UE, Comisia Europeană, Astra Locations: Moldova, Chișinău, Moderna, Sinovac, Federația Rusă, SUA, UE, . Moldova, Federației Ruse, AMDM, China

Search resuls for: "immuno"

16 mentions found